



Freedom of Information Team
De La Court House
Queen Alexandra Hospital
Southwick Hill Road
Portsmouth
Hampshire
PO6 3LY

Name:
Email:
Date: 27/06/2023
Ref: 23-24 167

Dear

RE: Freedom of Information request

Thank you for your request for information under the Freedom of Information Act 2000, which was received by the Trust on 15/06/2023. Please see responses to your requests below.

Q1 - How many patients has your Trust treated in the past 3 months for:

Please see below table.

Drugs	Patients
Non-small cell lung cancer (NSCLC) any treatment	<5
Non-small cell lung cancer (NSCLC) surgical treatment	0
Non-small cell lung cancer (NSCLC) radiotherapy	<5
Non-small cell lung cancer (NSCLC) systemic anti-cancer treatment (SACT)	<5

We are unable to provide precise figures when these are five or less due to the risk that individuals will be identified, as we are required to protect their identity under the Data Protection Act.

In such circumstances sections 40(2) and (3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle. This states that personal data should be processed fairly and lawfully. It is the fairness aspect of this principle which, in our view, would be breached by disclosure.

Q2 - How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

Please see below table.

Regimen	Patients
ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)	0
Amivantamab	<5
Atezolizumab monotherapy	0
Atezolizumab with chemotherapy	0
Dabrafenib + Trametinib	0
Durvalumab	0
Gemcitabine	0
Nitendanib + Docetaxel	0
Nivolumab	0
Osimertinib	0
Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)	0
Paclitaxel	0
Pembrolizumab monotherapy	0
Pembrolizumab with chemotherapy	<5
Pemetrexed with carboplatin/cisplatin	<5
RET Inhibitors (Pralsetinib, Selpercatinib)	0
Sotorasib	0
Tepotinib	0
Vinorelbine monotherapy or combination with Carboplatin/Cisplatin	<5
Other active systemic anti-cancer therapy [please state]	<5 (Capecitabine-Oxaliplatin)
Palliative care only	0

We are unable to provide precise figures when these are five or less due to the risk that individuals will be identified, as we are required to protect their identity under the Data Protection Act.

In such circumstances sections 40(2) and (3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle. This states that personal data should be processed fairly and lawfully. It is the fairness aspect of this principle which, in our view, would be breached by disclosure.

Q3 - Of the NSCLC patients treated with Nivolumab in the past 3 months, how many patients received (surgery) or are scheduled to receive surgical treatment after commencement of the treatment with Nivolumab?

No NSCLC patients treated with Nivolumab in the period.

Please accept this letter as completion of your request. Please note that copies of this request will be held on file for three years before being confidentially destroyed.

If you are dissatisfied with the outcome of your request, please contact our Head of Information Governance on Information.Governance@porthosp.nhs.uk or write to the above address and we will conduct an internal review. Upon review, if you are still dissatisfied, you may appeal our decision by contacting the Information Commissioner's Office; for more information, please visit the [ICO's website](#).

Please be aware, if we do not receive an appeal within 30 days of you receiving this letter, we will assume that you are satisfied with our response. If you have any further queries, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team